Seasonal malaria chemoprevention (SMC) effectively prevents malaria episodes and deaths in children during the high transmission season. However, adoption of SMC is challenged by parasite resistance to sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) in East and southern Africa. In Uganda’s Karamoja region, we evaluated SPAQ resistance marker changes in children 3–59 months during the 2021 (85,000 children) and 2022 (270,000 children) SMC rounds as part of a protective effectiveness study.
This poster was presented at the 72nd annual meeting of the American Society of Tropical Medicine and Hygiene.
Country: UgandaKeywords: ASTMH | Chemoprevention | Malaria | Treatment
« Back to Publications